Literature DB >> 23948248

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Yunyun Yuan1, Orgil Elbegdorj, Irina O Beletskaya, Dana E Selley, Yan Zhang.   

Abstract

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1'- or 4'-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQ analogues retained low efficacy at the MOR compared to NAQ in the (35)S-GTP[γS] binding assays while electron-withdrawing groups at 1'-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1'- or 4'-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation. Published by Elsevier Ltd.

Entities:  

Keywords:  Antagonists; MOR; NAQ; SAR

Mesh:

Substances:

Year:  2013        PMID: 23948248      PMCID: PMC3776595          DOI: 10.1016/j.bmcl.2013.07.043

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; Guo Li; Hengjun He; David L Stevens; Patrick Kozak; Krista L Scoggins; Pallabi Mitra; Phillip M Gerk; Dana E Selley; William L Dewey; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2011-05-06       Impact factor: 4.418

3.  Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.

Authors:  D Wang; K M Raehal; E J Bilsky; W Sadée
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

Review 4.  Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.

Authors:  Lara A Ray; Pauline F Chin; Karen Miotto
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

5.  Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.

Authors:  Danxin Wang; Xiaochun Sun; Wolfgang Sadee
Journal:  J Pharmacol Exp Ther       Date:  2007-01-31       Impact factor: 4.030

6.  Syntheses of novel high affinity ligands for opioid receptors.

Authors:  Mark P Wentland; Rongliang Lou; Qun Lu; Yigong Bu; Christoph Denhardt; Jin Jin; Rakesh Ganorkar; Melissa A VanAlstine; Chengyun Guo; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2009-02-25       Impact factor: 2.823

7.  Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.

Authors:  Senait Ghirmai; Marc R Azar; Wilma E Polgar; Ilona Berzetei-Gurske; John R Cashman
Journal:  J Med Chem       Date:  2008-02-26       Impact factor: 7.446

8.  Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.

Authors:  Andrea L Pelotte; Ryan M Smith; Mario Ayestas; Christina M Dersch; Edward J Bilsky; Richard B Rothman; Amy M Deveau
Journal:  Bioorg Med Chem Lett       Date:  2009-03-26       Impact factor: 2.823

9.  Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Jianyang Chen; Shashidhar K Akubathini; Feng Zhang; David L Stevens; Irina O Beletskaya; Krista L Scoggins; Zhenxian Zhang; Phillip M Gerk; Dana E Selley; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

10.  Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Authors:  Mariana Spetea; Falko Schüllner; Radu C Moisa; Ilona P Berzetei-Gurske; Barbara Schraml; Cynthia Dörfler; Mario D Aceto; Louis S Harris; Andrew Coop; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

View more
  7 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

3.  In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.

Authors:  Samuel Obeng; Yunyun Yuan; Abdulmajeed Jali; Dana E Selley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2018-03-09       Impact factor: 4.432

4.  Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.

Authors:  Edna J Santos; Matthew L Banks; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2022-04-30       Impact factor: 4.402

5.  Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.

Authors:  Boshi Huang; Rama Gunta; Huiqun Wang; Mengchu Li; Danni Cao; Rolando E Mendez; James C Gillespie; Chongguang Chen; Lan-Hsuan M Huang; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  Bioorg Chem       Date:  2021-02-09       Impact factor: 5.275

6.  Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.

Authors:  D E Selley; M L Banks; C M Diester; A M Jali; L P Legakis; E J Santos; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2020-12-22       Impact factor: 4.030

7.  An Integrated Approach toward NanoBRET Tracers for Analysis of GPCR Ligand Engagement.

Authors:  Michael P Killoran; Sergiy Levin; Michelle E Boursier; Kristopher Zimmerman; Robin Hurst; Mary P Hall; Thomas Machleidt; Thomas A Kirkland; Rachel Friedman Ohana
Journal:  Molecules       Date:  2021-05-12       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.